Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q4 2016 · 10-K
Revenue$28.73M$28.73M−7.0% vs Q4 2015 Net Income$8.09M$8.09M−26.8% vs Q4 2015 EPS Diluted$0.54$0.54−25.0% vs Q4 2015 Gross Profit$20,757,000+7.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$5,844,000−61.7% Free Cash Flowderived$4,438,000−45.1% Margins · derivedGross margin72.3%+9.7 pt vs Q4 2015
Operating margin44.4%−10.9 pt vs Q4 2015
Net margin28.1%−7.6 pt vs Q4 2015
ended Dec 31, 2016 · filed Feb 24, 2017 · 55 d after period end